Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects
| Autor: | Martin Smith, Zanele Nsingwane, Geoffrey P. Candy, J. Devar, Jones Omoshoro-Jones, Ekene Emmanuel Nweke |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Stromal cell Pancreatic ductal adenocarcinoma endocrine system diseases Immune checkpoint inhibitors medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Immune system Antineoplastic Agents Immunological Genetics medicine Animals Humans Molecular Biology business.industry Pancreatic Ducts General Medicine Immunotherapy digestive system diseases Clinical trial Pancreatic Neoplasms 030104 developmental biology 030220 oncology & carcinogenesis Cancer cell Cancer research business Carcinoma Pancreatic Ductal |
| Zdroj: | Molecular biology reports. 47(8) |
| ISSN: | 1573-4978 |
| Popis: | Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest human malignancies with a dismal prognosis. During PDAC progression, the immune response is affected as cancer cells evade detection and elimination. Recently, there have been advances in the treatment of PDAC using immunotherapy, although a lot more work is yet to be done. In this review, we discuss these advances, challenges and potentials. We focus on existing and potential immune targets for PDAC, drugs used to target them, and some clinical trials conducted so far with them. Finally, novel targets in the tumour microenvironment such as stromal cells and other potential future areas to explore including bacterial therapy and the use of neoantigens in immunotherapy are highlighted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink